Europe & The Storm Ahead - Research Report on Amgen, Inc. and Biogen Idec Inc.
(firmenpresse) - MACAU -- (Marketwire) -- 08/16/11 -- Today, announced its research report highlighting Amgen, Inc. (NASDAQ: AMGN) and Biogen Idec Inc. (NASDAQ: BIIB). Full content and research is available at .
Continued confidence in long-term U.S. debt is defying S&P's recent downgrade. Treasury yields continue at their lowest levels since January 1, 2011 as the market moved to "safe investments" weary of the storm clouds ahead. Winds can change however, as a last-minute move to save the U.S. from a historic default on its debt obligations. Attentions are now turned to the situation in Europe, with the health of the Euro in the balance; bankers are looking to prevent defaults on Italian and Spanish debt.
As a result of recent credit adjustments, opportunity is being marked for investors to take advantage of equities with high-margin and specialty products. Market-wise investors are carefully watching for value within equities boasting established pipelines and excellent growth prospects. As part of this process, the following companies have been introduced with initial research reports available online.
Equity Markets has reviewed Amgen, Inc. as an independent biotechnology medicines company. Amgen discovers, develops, manufactures and markets medicines for grievous illnesses. It focuses on human therapeutics and concentrates on medicines based on advances in cellular and molecular biology. The full research report on Amgen, Inc. (NASDAQ: AMGN) is available here: .
Equity Markets is covering Biogen Idec Inc. as a global biotechnology company focused on discovering, developing, manufacturing and marketing products for the treatment of neurological disorders and other serious diseases. The full research report on Biogen Idec Inc. (NASDAQ: BIIB) is available here: .
About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.
Contact:
Samuel Littman
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 16.08.2011 - 07:00 Uhr
Sprache: Deutsch
News-ID 1031009
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
MACAU
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 133 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Europe & The Storm Ahead - Research Report on Amgen, Inc. and Biogen Idec Inc.
"
steht unter der journalistisch-redaktionellen Verantwortung von
Equity Markets Inc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
